Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London.

BJGP open·2026
Same author

Using an artificial intelligence-based device to investigate pain outcomes in robotic prostatectomy at low pressure pneumoperitoneum: The RALP clinical trial.

BJUI compass·2026
Same author

Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.

JMIR AI·2026
Same author

AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.

European radiology·2026
Same author

Training and external validation of machine learning supervised prognostic models of upper tract urothelial cancer (UTUC) after nephroureterectomy.

Scientific reports·2026
Same author

A multi-modal approach for decision making in bladder cancer.

Nature reviews. Urology·2026
Same journal

Normal Reference Values for Testicular Volume in Adult Somali Men: A Retrospective Study.

Research and reports in urology·2026
Same journal

Vacuum-Assisted Mini-PCNL is Associated with Lower Postoperative SIRS: A Real-World Cohort Study.

Research and reports in urology·2026
Same journal

Assessing the Knowledge and Awareness of Urinary Incontinence Among Urogynecology Clinic Patients in Jordan: A Cross-Sectional Study.

Research and reports in urology·2026
Same journal

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Research and reports in urology·2026
Same journal

Hydrocelectomy Complication Rates in the United States.

Research and reports in urology·2026
Same journal

Artificial Intelligence as a Diagnostic Tool for Benign Prostatic Hyperplasia (BPH): A Narrative Review.

Research and reports in urology·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Immunotherapy for bladder cancer.

Oliver Fuge1, Nikhil Vasdev1, Paula Allchorne2

  • 1Department of Urology, Lister Hospital, Stevenage, UK.

Research and Reports in Urology
|May 23, 2015
PubMed
Summary
This summary is machine-generated.

For nearly 40 years, Bacillus Calmette-Guérin (BCG) immunotherapy has been the gold standard for superficial bladder cancer. Despite limitations like toxicity and non-response, research explores new treatments and BCG enhancements.

Keywords:
Bacillus Calmette–Guerinbladder cancerimmunotherapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Area of Science:

  • Immunology
  • Oncology
  • Urology

Background:

  • Bacillus Calmette-Guérin (BCG) has been the primary immunotherapy for superficial bladder cancer for approximately 40 years.
  • Despite its efficacy, BCG has limitations including toxicity and a significant non-response rate, posing challenges in clinical practice.

Purpose of the Study:

  • To review the established mechanism of action of BCG in bladder cancer.
  • To discuss the clinical aspects of BCG, including its effectiveness, optimal treatment, toxicity, and strain variations.
  • To explore novel immunotherapies and alternative treatments being developed to address BCG's limitations.

Main Methods:

  • Review of existing evidence on BCG's mechanism of action and clinical outcomes.
  • Analysis of immune molecules implicated in BCG's efficacy.
  • Examination of emerging alternative therapies and modifications of BCG treatment.

Main Results:

  • BCG activates a broad array of immune molecules, contributing to its anti-cancer effects.
  • Optimal dosing and protocols are better understood, but toxicity and non-response remain significant issues.
  • New approaches, including BCG augmentation and alternative therapies like gene, virus, and photodynamic therapy, are under investigation.

Conclusions:

  • BCG remains a cornerstone treatment for superficial bladder cancer despite its limitations.
  • Ongoing research focuses on overcoming BCG's toxicity and non-response through novel immunotherapies and treatment modifications.
  • The development of immune checkpoint inhibitors shows promise, particularly in metastatic disease, but their role in superficial bladder cancer requires further study.